Non-Invasive Ventilation (NIV)
Treatment for Motor Neuron Disease
Typical Dosage: Titrated positive airway pressure based on patient need
Effectiveness
90%
Safety Score
85%
Clinical Trials
39
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe
Treatment Details
Dosage Range
Titrated positive airway pressure based on patient need
Time to Effect
Immediate for symptom relief, months for survival benefit
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$2,800
Side Effect Mgmt:$200
Total Annual:$3,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$4,286
Comparison vs No Non-Invasive Ventilation
Cost Difference
+$3,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Non-Invasive Ventilation (NIV) Outcomes
for Motor Neuron Disease
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+70%
Common Side Effects
Facial skin irritation
+30%
Dry mouth
+20%
Bloating/gastric distension
+15%
Mask discomfort
+10%
Active Clinical Trials
6 active trials recruiting for Non-Invasive Ventilation (NIV) in Motor Neuron Disease
Home Versus Hospital Based NIV Care in MND
NCT06844370RECRUITINGNA
60 participants
INTERVENTIONAL
Cambridge, United Kingdom
Started: Mar 6, 2024
Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease
NCT05136222RECRUITINGNA
244 participants
INTERVENTIONAL
Adelaide, Australia +12 more
Started: Dec 15, 2021
A Pilot Randomized Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
NCT07071935NOT YET RECRUITINGPHASE2
48 participants
INTERVENTIONAL
Hershey, United States +2 more
Started: Nov 1, 2025
Optimizing INITIation of Non-invasive Ventilation in ALS Patients
NCT05033951RECRUITING
250 participants
OBSERVATIONAL
Groningen, Netherlands
Started: Aug 1, 2022
Dynamic Impact of NIV on Diaphragmatic Ultrasound in Patients With Amyotrophic Lateral Sclerosis
NCT07170865NOT YET RECRUITING
20 participants
OBSERVATIONAL
Grenoble, France
Started: Sep 1, 2025
Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation
NCT05621213RECRUITINGNA
40 participants
INTERVENTIONAL
Grenoble, France +1 more
Started: Jan 13, 2023
Completed Clinical Trials
6 completed trials for Non-Invasive Ventilation (NIV) in Motor Neuron Disease
The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease
NCT03444428COMPLETED
13 participants
OBSERVATIONAL
London, United Kingdom +1 more
Started: Feb 21, 2017
"New Perspectives of Adaptation to NIV in ALS"
NCT02537132COMPLETEDNA
48 participants
INTERVENTIONAL
Lumezzane, Italy +1 more
Started: Jan 1, 2015
Exploratory Study of Respiratory Bacterial Infections or Superinfections and Colonizations in Patients With Spinal Muscular Atrophy Under NIV
NCT05712330COMPLETEDNA
8 participants
INTERVENTIONAL
Amiens, France
Started: Jan 24, 2023
EncoreAnywhere Use in Motor Neurone Disease
NCT03154450COMPLETEDNA
19 participants
INTERVENTIONAL
Sheffield, United Kingdom
Started: Jan 21, 2016
Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis
NCT00958048COMPLETEDNA
70 participants
INTERVENTIONAL
Taipei, Taiwan
Started: Jan 1, 2009
Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode
NCT01746381COMPLETEDNA
30 participants
INTERVENTIONAL
Montreal, Canada
Started: Feb 1, 2014
Showing 20 of 39 total trials